Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Impact · against what's priced in

The recent inflows into LABU and XBI reflect short-term tactical bets on a biotech rebound rather than a fundamental shift in long-term conviction. While LABU saw a significant proportional increase in assets, the underlying volatility decay makes it a poor long-term vehicle, limiting the impact of these flows to short-term momentum.

XBI+0.20

No priced-in read yet